Opinion statement
Stiff-person syndrome (SPS) is a progressive neurologic disorder characterized by 1) stiffness that is prominent in axial muscles, with co-contraction of agonist and antagonist muscles; 2) sudden episodic spasms; and 3) absence of another disease that causes similar symptoms. The diagnosis of SPS is based on clinical grounds and requires a high degree of suspicion. The diagnosis is, however, aided by electromyography, which demonstrates motor unit firing at rest simultaneously from the agonist and antagonist muscles, and by high serum titers of antibodies against glutamic acid decarboxylase (GAD), the rate-limiting enzyme for the synthesis of gamma-aminobutyric acid (GABA), which is the brain’s main inhibitory neurotransmitter. The reduced GABA level in the brain and cerebrospinal fluid explains the patients’ stiffness and justifies the clinical improvement observed by drugs enhancing GABAergic transmission. The association of SPS with other autoimmune disorders or autoantibodies, the intrathecal GAD-specific immunoglobulin G antibody synthesis, and the suppression of GABA by the patient’s antibodies supports the autoimmune nature of SPS and justifies the use of immunotherapies. At present, GABA-enhancing agents, such as benzodiazepines, valproate, vigabatrin, tiagabine, gabapentin, and baclofen, provide symptomatic relief. Plasmapheresis, steroids, and periodic intravenous immunoglobulin infusions provide additional and lasting benefit. In this article, the treatment options for patients with SPS are discussed based on the authors’ experience and that of others. The beneficial effects from the first controlled study conducted in SPS using intravenous immunoglobulin are presented.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Moersh FP, Woltman HW: Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome): report of a case and some observations in 13 other cases. Mayo Clin Proc 1956, 31:421–427.
Lorish TR, Thorsteinsson G: Stiff-man syndrome: updated. Mayo Clin Proc 1989, 64:629–636.
McEvoy K: Stiff-man syndrome. Mayo Clin Proc 1991, 66:300–304.
Toro C, Jacobowitz DM, Hallet M: Stiff-man syndrome. Semin Neurol 1994, 154:157–158.
Levy LM, Dalakas MC, Floeter MK: The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999, 131:522–530.
Dalakas MC, Fujii M, Li M, et al.: The clinical spectrum of anti-GAD antibody-positive patients with stiffperson syndrome. Neurology 2000, 55:1531–1535.
Barker RA, Revesz T, Thom M, et al.: Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 1998, 65:633–640.
Meinck H-M, Ricker K, Conrad B: The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J Neurol Neurosurg Psychiatry 1984, 47:280–287.
Solimena M, Folli F, Denis-Donini S, et al.: Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988, 318:1012–1020.
Solimena M, Folli F, Aparisi R, et al.: Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiffman syndrome. N Engl J Med 1990, 322:1555–1560.
De Camilli P, Thomas A, Cofiell R, et al.: The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993, 178:2219–2223.
Butler MH, Hayashi A, Ohkoshi N, et al.: Autoimmunity to gephyrin in stiff-man syndrome. Neuron 2000, 26:307–312.
Dalakas MC, Li M, Fujii M, et al.: Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 2001, 57:780–784. The study showed intrathecal production of anti-GAD antibodies in SPS patients and reduction of the GABA level in the cerebrospinal fluid. The significance of anti-GAD antibodies in the autoimmunity of SPS was discussed.
Brown P, Marsden CD: The stiff man and stiff man plus syndromes. J Neurol 1999, 246:648–652.
Shaw PJ: Stiff-man syndrome and its variants. Lancet 1999, 353:86–87.
Saiz A, Graus F, Valldeoriola F, et al.: Stiff-leg syndrome: a focal form of stiff-man syndrome. Ann Neurol 1998, 43:400–403.
Howard FM, Jr: A New and effective drugs in the treatment of stiff-man syndrome: preliminary report. Proc Mayo Clinic 1963, 38:203–212.
Cohen L: Stiff-man syndrome: two patients treated with diazepam. JAMA 1966, 195:160–162.
Olafson RA, Mulder DW, Howard FM: “Stiff-man” syndrome: a review of the literature, report of three additional cases and discussion of pathophysiology and therapy. Mayo Clin Proc 1964, 39:131–44.
Westblom Ulf: Stiff-man syndrome and clonazepam. JAMA 1977, 237:1930.
Spehlmann R, Norcross K, Rasmus SC, et al.: Improvement of stiff-man syndrome with sodium valproate. Neurology 1981, 31:1162–1163.
Ben-Menachem E, Person LI, Mumford J, et al.: Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J Child Neurol 1991, 2(suppl):S11-S16.
Vermeij FH, van Doorn PA, Busch HF: Improvement of stiff-man syndrome with vigabatrin. Lancet 1996, 348:612.
Prevett MC, Brown P, Duncan JS: Improvement of stiffman syndrome with vigabatrin. Neurology 1997, 48:1133–1134.
Sharoqi IA: Improvement of stiff-man syndrome with vigabatrin. Neurology 1998, 50:833–834.
Murinson BB, Rizzo M: Improvement of stiff-person syndrome with tiagabine. Neurology 2001, 57:366. This is an interesting case report on the successful symptom management obtained with tiagabine on a patient with SPS.
Whelan JL: Baclofen in treatment of the stiff-man syndrome. Arch Neurol 1980, 37:600–601.
Miller F, Korsvik H: Baclofen in the treatment of stiff-man syndrome. Ann Neurol 1981, 9:511–512.
Penn RD, Mangieri EA: Stiff-man syndrome treated with intrathecal baclofen. Neurology 1993, 43:2412.
Seitz RJ, Blank B, Kiwit JC, et al.: Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. Neurology 1995, 242:618–622.
Silbert PL, Matsumoto JY, McManis PG, et al.: Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology 1995, 45:1893–1897.
Stayer C, Tronnier V, Dressnandt J, et al.: Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalopathy with rigidity and myoclonus. Neurology 1997, 49:1591–1597.
Voci JM, al-Hakim M, Dokko Y, et al.: Intravenous methocarbamol in the treatment of stiff-man syndrome. Muscle Nerve 1993, 16:434–435.
Davis D, Jabbari B: Significant improvement of stiffperson syndrome after paraspinal injection of botulinum toxin A. Mov Disord 1993, 8:371–373.
Liguori R, Cordivari C, Lugaresi E, et al.: Botulinum toxin A improves muscle spasms and rigidity in stiffperson syndrome. Mov Disord 1997, 12:1060–1063.
Brown P, Thompson PD, Rothwell JC, et al.: A therapeutic trial of milacemide in myoclonus and the stiffperson syndrome. Mov Disord 1991, 6:73–75.
Ellis MT, Atkinson AM: The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med 1996, 2:148–153.
Daw K, Ujihara N, Atkinson M, Powers AC: Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996, 156:818–825.
Dinkel KMH, Jury KM: Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998, 44:194–201.
Ishida K, Mitoma H, Song SY, et al.: A elective suppression of cerebellar gabaergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 1999, 46:263–267.
George TM, Burke JM, Sobotka PA, et al.: Resolution of stiff-man syndrome with cortisol replacement in a patient with deficiencies of ACTH, growth hormone, and prolactin. N Engl J Med 1984, 310:1511–1513.
Piccolo G, Cosi V, Zandrini C, et al.: Steroid-responsive and dependent stiff-man syndrome: a clinical and electrophysiologic study of two cases. Ital J Neurol Sci 1988, 9:559–566.
Hummel M, Durinovic-Bello I, Bonifacio E, et al.: Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus. J Neurol Neurosurg Psychiatry 1998, 65:204–208.
Dalakas MC: Neuroimmunotherapy: a practical approach to the treatment of immune-mediated neurological diseases. Semin Neurol 1994, 14:97–105.
Hao W, Davis C, Hirsch IB, et al.: Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study. J Neurol 1999, 246:731–735.
Vicari AM, Folli F, Pozza G, et al.: Plasmapheresis in the treatment of stiff-man syndrome [letter]. N Engl J Med 1989, 320:1499.
Harding AE, Thompson PD, Kocen RS, et al.: Plasma exchange and immunosuppresion in the stiff man syndrome. Lancet 1989, 14:915.
Gordon MF, Pullman S, McDonald T, et al.: Plasmapheresis in the treatment of stiff-man syndrome. Neurology 1991, 41(suppl):223.
Brashear R, Phillips II HL: Autoantibodies to gabaergic neurons and response to plasmapheresis in stiff-man syndrome. Neurology 1991, 41:1588–1592.
Nakamagoe K, Ohkoshi N, Hayashi A, et al.: Marked clinical improvement by plasmapheresis in a patient with stiff-man syndrome: a case with a negative anti-GAD antibody. Rinsho Shinkeigaku 1995, 35:897–900.
Fogan L: Progressive encephalomyelitis with rigidity responsive to plamapheresis and immunosuppression. Ann Neurol 1996, 40:451–453.
Hayashi A, Nakamagoe K, Ohkoshi N, et al.: Double filtration plasma exchange and immunoadsorption therapy in a case of stiff-man syndrome with negative anti-GAD antibody. J Med 1999, 30:321–327.
Shariatmadar S, Noto TA: Plasma exchange in stiff-man syndrome. Ther Apher 2001, 5:64–67. The potential role of plasmapheresis in patients with SPS was discussed.
Karlson EW, Sudarsky L, Ruderman E, et al.: Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum 1994, 37:915–918.
Amato AA, Cornman EW, Kissel JT: Treatment of stiffman syndrome with intravenous immunoglobulin. Neurology 1994, 44:1652–1654.
Barker RA, Marsden CD: Successful treatment of stiff man syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997, 62:426–427.
Sevrin C, Moulin T, Tatu L, et al.: “Stiff-man” syndrome treated with intravenous immunoglobulins. Rev Neurol (Paris) 1998, 154:431.
Khanlou H, Eiger G: Long-term remission of refractory stiff-man syndrome after treatment with intravenous immunoglobulin. Mayo Clin Proc 1999, 74:1231–1232.
Souza-Lima CF, Ferraz HB, Braz CA, et al.: Marked improvement in a stiff-limb patient treated with intravenous immunoglobulin. Mov Disord 2000, 15:358–359.
Molina JA, Porta J, Garcia-Morales I, et al.: Treatment with intravenous prednisone and immunoglobulin in a case of progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2000, 68:395–396.
Mikaeloff Y, Jambaque I, Mayer M, et al.: Benefit of intravenous immunoglobulin in autoimmune stiffperson syndrome in a child. J Pediatr 2001, 139:340. The benefit of IVIG in stiff-child syndrome is reported in an open-label study.
Dalakas MC, Fujii M, Li M, et al.: High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001, 345:1870–1876. This is the first controlled study in SPS. It shows that IVIG is effective in the disease using new markers for stiffness and heightened sensitivity. The results are important because they offer an effective therapy and because they confirm that immune-mediated mechanisms play a pathogenetic role in the disease. The findings open the avenue for future immunomodulatory therapies or combination therapies.
Dalakas MC: Intravenous immuno globulin therapy for neurological diseases. Ann Intern Med 1997, 126:721–730.
Yu Z, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999, 340:227–228.
Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immuno globulin. N Eng J Med 2001, 345:747–755. A comprehensive review of the mechanism of action of IVIG.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vasconcelos, O.M., Dalakas, M.C. Stiff-person syndrome. Curr Treat Options Neurol 5, 79–90 (2003). https://doi.org/10.1007/s11940-003-0024-x
Issue Date:
DOI: https://doi.org/10.1007/s11940-003-0024-x